Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06028412Enrolling by invitation
Lobectomy vs. Sublobar Resection for Small NSCLC
This trial compares two types of lung surgery for early-stage non-small cell lung cancer. You may qualify if you have a small tumor (2 cm or less) with specific features on a CT scan. The goal is to see which surgery offers better outcomes.
Xi'an, ShannxiAges 18–75 - NCT06017869RecruitingPhase 2
Mitochondria therapy for Pearson Syndrome in children
This trial tests a one-time infusion of your own blood cells mixed with donated mitochondria to see if it can help children with Pearson Syndrome grow better and improve their health. It is a new approach that aims to provide the energy your cells need.
Ramat Gan, IsraelAges 1–18 - NCT06010329RecruitingPhase 2
Study of a new pill for advanced lung cancer with rare EGFR mutations
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
Glendale, CaliforniaAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT05987826RecruitingPhase 2
Furmonertinib before surgery for EGFR-mutant lung cancer
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
ShanghaiAges 18–75 - NCT05990946Recruiting
Smartphone symptom check-ins to improve recovery exercises after lung surgery
This trial tests whether using a smartphone app to report symptoms can help patients stick to their recovery exercises after minimally invasive lung cancer surgery. If you are having surgery for lung cancer, this study may help you recover better at home.
Zhongshan, GuangdongAges 18–75 - NCT05989828RecruitingPhase 1
Engineered immune cells for advanced triple-negative breast cancer
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05952934RecruitingPhase 2
Vaccine trial to help prevent head and neck cancer return
This Phase 2 study tests a Candida-based vaccine to help stop head and neck squamous cell cancer from coming back after curative treatment. If you are currently cancer-free on scans and exams, the trial may help train your immune system to lower recurrence risk.
Fayetteville, ArkansasAges 18–100 - NCT05947136Recruiting
PASCA program study after stem cell transplant for myeloma
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
ÉpagnyAges 18–70 - NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05965557Recruiting
Markers that predict response to immunotherapy before lung surgery
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
ShanghaiAges 18–80 - NCT05958121RecruitingPhase 1/Phase 2
IMA402 immune therapy for advanced solid tumors
This trial tests an immune system treatment (IMA402) that is meant to help the body recognize and fight advanced solid tumors. It may be an option if your cancer has come back or did not respond to standard treatments, and if your overall health and tumor measurements meet study requirements.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05951777RecruitingPhase 2
Stem cells from your own fat for chronic brain injury
This trial tests whether stem cells taken from your own fat and given through an IV can help people with long-term brain damage from a head injury. It is for adults who have not gotten better with standard treatments.
Houston, TexasAges 18–55 - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT05925036RecruitingPhase 1
Cell therapy trial for pain from long-term pancreatitis
This Phase 1 study tests a new cell-based treatment to reduce pain caused by chronic pancreatitis. It’s designed mainly to check safety first, and it may help people with ongoing, opioid-stable pancreatic pain.
Charleston, South CarolinaAges 18–75 - NCT05935384Recruiting
Blood tests to track response to cancer therapy
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
Skokie, IllinoisAges 18 years+ - NCT05918523Recruiting
Long-term follow-up for people treated with REACT
This study checks long-term health outcomes in people who previously received a treatment called REACT for chronic kidney disease. It may help doctors understand how safe and effective REACT is over time.
Meridian, IdahoAges 30–80 - NCT05924477Recruiting
Compare glaucoma shunt options to prevent cell loss
This study compares a glaucoma drainage device approach to see which one better prevents loss of corneal cells after surgery. You may benefit by receiving close monitoring around the time of glaucoma surgery and helping doctors improve surgical choices.
San Francisco, CaliforniaAges 18 years+ - NCT05917106Recruiting
Testifying methylomics blood test for new kidney cancer monitoring
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Nanjing, JiangsuAges Any age - NCT05915208Recruiting
Follow-up study for people with histiocytic disorders
This study is checking in over time with people who have a histiocytic disorder. It may help doctors better understand how these conditions behave and what follow-up care works best.
Birmingham, AlabamaAges birth–89 years - NCT05923970Recruiting
MMRV vaccine booster in pregnant adults in Alberta
This study looks at whether getting a third dose of the MMRV vaccine during pregnancy is helpful. It focuses on pregnant women who were screened for rubella immunity during routine prenatal testing.
Edmonton, AlbertaAges 18 years+ - NCT05919290Recruiting
Study MRI imaging markers in head and neck cancer
This study uses repeat MRI scans to look for imaging “markers” that may help doctors better understand head and neck squamous cell cancer. It may be most relevant if you are planning curative surgery and/or (chemo)radiotherapy and can safely undergo MRI more than once.
Toronto, OntarioAges 18 years+ - NCT05933239RecruitingPhase 2
PET-like scan using a special protein in lung cancer
This Phase 2 study tests whether a new imaging medicine (a radiopharmaceutical) can highlight immune cells called macrophages in people with non-small cell lung cancer. It may help doctors better “see” and evaluate tumor tissue before a surgical biopsy or removal.
Jette, Brussels CapitalAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.